Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol
Introduction The exact role of hepatic arterial infusion chemotherapy (HAIC) in advanced hepatocellular carcinoma (aHCC) is still unknown. The combination of HAIC and sorafenib has been proven to be more effective than sorafenib alone in the first-line treatment of aHCC. The aim of the study is to e...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/12/e080805.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850243929815908352 |
|---|---|
| author | Wei Sun Xiao Li Tao Gong He Zhao Xiaowu Zhang Pengfei Tian Yingen Luo Jingui Li Zhengqiang Yang Peng Song |
| author_facet | Wei Sun Xiao Li Tao Gong He Zhao Xiaowu Zhang Pengfei Tian Yingen Luo Jingui Li Zhengqiang Yang Peng Song |
| author_sort | Wei Sun |
| collection | DOAJ |
| description | Introduction The exact role of hepatic arterial infusion chemotherapy (HAIC) in advanced hepatocellular carcinoma (aHCC) is still unknown. The combination of HAIC and sorafenib has been proven to be more effective than sorafenib alone in the first-line treatment of aHCC. The aim of the study is to evaluate the efficacy and safety of HAIC plus regorafenib in the second-line treatment of aHCC.Methods and analysis This is a multicenter, open-label, randomised controlled phase III trial. A total of 294 patients with aHCC, who are unable to tolerate the first-line systemic therapy or progress after the first-line systemic therapy, will be enrolled in the study. The patients will be randomly (2:1) assigned into the combination treatment group (HAIC plus regorafenib, n=196) and the control group (regorafenib alone, n=98). HAIC and regorafenib (160 mg/day) will be given in a 4-week cycle. The primary endpoint is overall survival in the intention-to-treat population. The second endpoints include progression-free survival, overall response rate, time to progression, etc. The radiological assessments will be based on the criteria of Response Evaluation Criteria in Solid Tumors 1.1.Ethics and dissemination This study is approved by the ethics committee of Cancer Hospital, Chinese Academy of Medical Sciences. All participants are required to provide written informed consent. The results of this study will be disseminated through peer-reviewed publications and esteemed academic conferences.Trial registration number Chinese Clinical Trial Registry (ChiCTR2300073075). |
| format | Article |
| id | doaj-art-e595ad5441eb40e1bc87532a5996f8d0 |
| institution | OA Journals |
| issn | 2044-6055 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-e595ad5441eb40e1bc87532a5996f8d02025-08-20T01:59:52ZengBMJ Publishing GroupBMJ Open2044-60552024-12-01141210.1136/bmjopen-2023-080805Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocolWei Sun0Xiao Li1Tao Gong2He Zhao3Xiaowu Zhang4Pengfei Tian5Yingen Luo6Jingui Li7Zhengqiang Yang8Peng Song92 Biomanufacturing Center, Department of Mechanical Engineering, Tsinghua University, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, ChinaIntroduction The exact role of hepatic arterial infusion chemotherapy (HAIC) in advanced hepatocellular carcinoma (aHCC) is still unknown. The combination of HAIC and sorafenib has been proven to be more effective than sorafenib alone in the first-line treatment of aHCC. The aim of the study is to evaluate the efficacy and safety of HAIC plus regorafenib in the second-line treatment of aHCC.Methods and analysis This is a multicenter, open-label, randomised controlled phase III trial. A total of 294 patients with aHCC, who are unable to tolerate the first-line systemic therapy or progress after the first-line systemic therapy, will be enrolled in the study. The patients will be randomly (2:1) assigned into the combination treatment group (HAIC plus regorafenib, n=196) and the control group (regorafenib alone, n=98). HAIC and regorafenib (160 mg/day) will be given in a 4-week cycle. The primary endpoint is overall survival in the intention-to-treat population. The second endpoints include progression-free survival, overall response rate, time to progression, etc. The radiological assessments will be based on the criteria of Response Evaluation Criteria in Solid Tumors 1.1.Ethics and dissemination This study is approved by the ethics committee of Cancer Hospital, Chinese Academy of Medical Sciences. All participants are required to provide written informed consent. The results of this study will be disseminated through peer-reviewed publications and esteemed academic conferences.Trial registration number Chinese Clinical Trial Registry (ChiCTR2300073075).https://bmjopen.bmj.com/content/14/12/e080805.full |
| spellingShingle | Wei Sun Xiao Li Tao Gong He Zhao Xiaowu Zhang Pengfei Tian Yingen Luo Jingui Li Zhengqiang Yang Peng Song Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol BMJ Open |
| title | Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol |
| title_full | Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol |
| title_fullStr | Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol |
| title_full_unstemmed | Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol |
| title_short | Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol |
| title_sort | hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second line therapy for advanced hepatocellular carcinoma a randomised controlled trial protocol |
| url | https://bmjopen.bmj.com/content/14/12/e080805.full |
| work_keys_str_mv | AT weisun hepaticarterialinfusionchemotherapyplusregorafenibcomparedwithregorafenibaloneassecondlinetherapyforadvancedhepatocellularcarcinomaarandomisedcontrolledtrialprotocol AT xiaoli hepaticarterialinfusionchemotherapyplusregorafenibcomparedwithregorafenibaloneassecondlinetherapyforadvancedhepatocellularcarcinomaarandomisedcontrolledtrialprotocol AT taogong hepaticarterialinfusionchemotherapyplusregorafenibcomparedwithregorafenibaloneassecondlinetherapyforadvancedhepatocellularcarcinomaarandomisedcontrolledtrialprotocol AT hezhao hepaticarterialinfusionchemotherapyplusregorafenibcomparedwithregorafenibaloneassecondlinetherapyforadvancedhepatocellularcarcinomaarandomisedcontrolledtrialprotocol AT xiaowuzhang hepaticarterialinfusionchemotherapyplusregorafenibcomparedwithregorafenibaloneassecondlinetherapyforadvancedhepatocellularcarcinomaarandomisedcontrolledtrialprotocol AT pengfeitian hepaticarterialinfusionchemotherapyplusregorafenibcomparedwithregorafenibaloneassecondlinetherapyforadvancedhepatocellularcarcinomaarandomisedcontrolledtrialprotocol AT yingenluo hepaticarterialinfusionchemotherapyplusregorafenibcomparedwithregorafenibaloneassecondlinetherapyforadvancedhepatocellularcarcinomaarandomisedcontrolledtrialprotocol AT jinguili hepaticarterialinfusionchemotherapyplusregorafenibcomparedwithregorafenibaloneassecondlinetherapyforadvancedhepatocellularcarcinomaarandomisedcontrolledtrialprotocol AT zhengqiangyang hepaticarterialinfusionchemotherapyplusregorafenibcomparedwithregorafenibaloneassecondlinetherapyforadvancedhepatocellularcarcinomaarandomisedcontrolledtrialprotocol AT pengsong hepaticarterialinfusionchemotherapyplusregorafenibcomparedwithregorafenibaloneassecondlinetherapyforadvancedhepatocellularcarcinomaarandomisedcontrolledtrialprotocol |